Bonum CE

Bonum Continuing Education - Your 🏡 for accredited, 🆓, SoMe #CME
* Specialty handles 🩺 GI🩸Hem 🦠 ID 🧬Onc
Solving clinical 🧩. Opinions ≠ med advice.

[Bonum CE @BonumCe]

3/#MondayNightIBD
#CME🏅➡️https://t.co/RlcbsH495r
🔴Post #IBDPoll 2️⃣

In a patient with #Crohns  ileocolitis who lost response to IFX (therapeutic drug level, no antibodies),

What 2nd line biologic would have the highest efficacy?

[Bonum CE @BonumCe]

🤝Thanks for all your input!
👌Now let’s get your ?s answered
#MondayNightIBD ~ #IL23 & #IL23p19 in #IBD 🎥
w/⭐️@BattatMD4IBD & @DCharabaty

Supported by an edu grant from @EliLillyandCo

🖱️Click👇to watch
🗳️Answer 🎥#IBDPolls
🏆Claim��#CME from @G@Global_CME using🔗👇
https://t.co/PAroHO3q3t

[Bonum CE @BonumCe]

2/#CME➡️https://t.co/RlcbsH495r

🔴Post #IBDPoll 1️⃣
42yo new dx of UC pancolitis, was started on miri,  now in remission @ 1yr
He's anxious about his chances of remaining in remission over time

In #LUCENT RCT, what % of pts in remission at Wk52 remained in remission @ yr 2&3?

[Bonum CE @BonumCe]

@DrKrinaPatel @jmikhaelmd @JNJInnovMed 3/ #OncTwitter #mmsm
🫥Didn’t answer the pre-polls yet?
⏱️Do so now before moving on👉🔗
🔰https://t.co/HO4gViYoSG

🟠Next, let us know; what’s your specialty?

[Bonum CE @BonumCe]

#NDMM Quad Tx Efficacy 🎥 Discussion w/ @DrKrinaPatel & @JMikhaelMD #MMSM https://t.co/RpWF06C9ix

[Bonum CE @BonumCe]

2/🥼Tune in to learn about efficacy of quad tx in #NDMM w⭐️ @DrKrinaPatel & @JMIkhaelMD

🚦3 quick steps &🆓 #CME
🔴Watch🎥⬆️
🟡Answer post-poll
🟢🏆Claim CME from @BonumCE👉https://t.co/YlFhtwPZ43
Supported by an edu grant from @JNJInnovMed

[Krina Patel @DrKrinaPatel]

#MMSM #OncTwitter #oncX
⚡️Join me & my colleague @jmikhaelmd

🧵Explore efficacy of quad tx in #NDMM
🔬PERSEUS, GMMG-HD7 & CONCEPT, CEPHEUS, IMROZ, ADVANCE, MIDAS +++

🆓#CME 👉🏼 https://t.co/IMMD4ah3sW
Supported by an edu grant from @JNJInnovMed

📍First, what's your specialty?

[Krina Patel @DrKrinaPatel]

2/ Before we jump in, a few disclosures & important links🔗

1️⃣📖#CME info https://t.co/IMMD4ah3sW
2️⃣Take the pre-survey👉https://t.co/Cuy0bck3jI
3️⃣Get the latest NDMM quad tx efficacy data w/ 🧵👇
4️⃣🏆Claim🆓CME https://t.co/WGgowxlfz1

Now, let's get started!

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME 3/ 🥼In your practice, which regimen are you using most often for 1L therapy in pts w/ transplant eligible(TE) #NDMM?

☎️Phoning friends…What do you do? @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT 4/💃Quads are taking center stage in #NDMM
Let’s look @ the📈on quad tx

PERSEUS ~🔑trial: SQ dara➕VRd➡️↑outcomes in TE pts

👉↑PFS @ 48m 84.3 v 67.7%; HR: 0.42; P<0.001
👉↑MRD- rate 75.2 v 47.5%; P<0.001
👉↑CR rate 87.9 v 70.1%; P<0.001
🎉🆕SOC ~ quad instead of triplet🎉

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT @AnnemiekBroijl @H_Einsele @PerrotAurore @paurotero @MyelomaOslo @mvmateos @AjayNookaMD @Bethfaiman 5/PERSEUS #ASCO25: sustMRD- in pts on quad maint @ median f/u 47.5m

↑ ustMRD- @ ≥24m w DVRd v VRd: 55.8 v 22.6%
👉Pts w ≥12m sustMRD-: ↑ 48m PFS,regardless of tx
👉Only 3.1% progressn @18m w DVRd v 6.8% VRd
🔑DVRd➡️2.5x⬆️≥24m sustMRD- & ½ progressn risk @≤18m tx
@mbeksac56

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT @AnnemiekBroijl @H_Einsele @PerrotAurore @paurotero @MyelomaOslo @mvmateos @AjayNookaMD @Bethfaiman @18m @mbeksac56 @hhashmi87 @docbraunstein @nsc_natalie @FaithEDavies1 @IreneGhobrial @SLentzsch 6/🙋🏻What about replacing dara- with isa- in a quad?

GMMG-HD7: IsaVRd v VRd induction➡️isa-len v len maintenance in TE NDMM

👉↑ MRD- rate 50% v 36%; p =0.00017
👉IsaVRd had ↓AE rates & ↓d/c rates v RVd

🎉🆕SOC
👉Results➡️addition of IsaVRd as induction regimen for TE #NDMM

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT @AnnemiekBroijl @H_Einsele @PerrotAurore @paurotero @MyelomaOslo @mvmateos @AjayNookaMD @Bethfaiman @18m @mbeksac56 @hhashmi87 @docbraunstein @nsc_natalie @FaithEDavies1 @IreneGhobrial @SLentzsch 7/⚡️GMMG-HD7 #ASCO25 update w/ PFS benefit in all quad recipients

↑CR 43.5% w IsaVRd v 34% w VRd
↑MRD- rate 66.2% w quad v 47.7% w triplet
👉PFS at 3yr benefit: 83% v 75% w/IsaVRd v VRd
↑MRD- regardless of maint v MRD+ (HR 0.61; P=0.002)
🔮Maint w Isa-len v len is on-going

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT @AnnemiekBroijl @H_Einsele @PerrotAurore @paurotero @MyelomaOslo @mvmateos @AjayNookaMD @Bethfaiman @18m @mbeksac56 @hhashmi87 @docbraunstein @nsc_natalie @FaithEDavies1 @IreneGhobrial @SLentzsch @EliasKarlMai @andrew02114 @SurbhiSidanaMD @UrviShahMD @DrRakeshPopat @Dr_AmerZeidan @HarethNahi 8/🔬Exciting news for #mmsm
Quad tx as🆕SOC for #NDMM

Current @EHA_Hematology/@EMN_EuMMnet (1st optn) & @NCCN (pref,cat 1) regimens for TE pts w/NDMM:
🎯DaraVRd➡️SCT➡️len maint
🎯IsaVRd SCT➡️len maint

👏to quad as 1L for TE pts👏
…but what about pts who are TIE /SCT-deferred?

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT @AnnemiekBroijl @H_Einsele @PerrotAurore @paurotero @MyelomaOslo @mvmateos @AjayNookaMD @Bethfaiman @18m @mbeksac56 @hhashmi87 @docbraunstein @nsc_natalie @FaithEDavies1 @IreneGhobrial @SLentzsch @EliasKarlMai @andrew02114 @SurbhiSidanaMD @UrviShahMD @DrRakeshPopat @Dr_AmerZeidan @HarethNahi @EHA_Hematology @EMN_EuMMnet @NCCN 9/CEPHEUS compared induction/consolidation w VRd ± daratumumab (D) followed by maintenance in transplant-ineligible (TIE) NDMM

🗳️The DVRd arm demonstrated which of the following outcomes?

@AlGarfall @bdermanmd @mvmateos @OcioEnrique
#OncTwitter #OncX #Oncology #MedTwitter

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT @AnnemiekBroijl @H_Einsele @PerrotAurore @paurotero @MyelomaOslo @mvmateos @AjayNookaMD @Bethfaiman @18m @mbeksac56 @hhashmi87 @docbraunstein @nsc_natalie @FaithEDavies1 @IreneGhobrial @SLentzsch @EliasKarlMai @andrew02114 @SurbhiSidanaMD @UrviShahMD @DrRakeshPopat @Dr_AmerZeidan @HarethNahi @EHA_Hematology @EMN_EuMMnet @NCCN @AlGarfall @bdermanmd @OcioEnrique 10/ CEPHEUS🔑trial in TIE & SCT-deferrd pts
DVRd➡️deeper, more durable MRD- rate

TIE cohort:
👉Overall MRD- 63.2 v 41.4%
👉SustMRD @ ≥12m 48.7 v 26.3%; P<0.0001
👉CR 81.2 v 61.6%; P<0.0001
👉HR 0.57, 95% CI 0.41-0.79; P=0.0005
↓D/C rate w quad

🎉DVRd new SOC for TIE NDMM🎉

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT @AnnemiekBroijl @H_Einsele @PerrotAurore @paurotero @MyelomaOslo @mvmateos @AjayNookaMD @Bethfaiman @18m @mbeksac56 @hhashmi87 @docbraunstein @nsc_natalie @FaithEDavies1 @IreneGhobrial @SLentzsch @EliasKarlMai @andrew02114 @SurbhiSidanaMD @UrviShahMD @DrRakeshPopat @Dr_AmerZeidan @HarethNahi @EHA_Hematology @EMN_EuMMnet @NCCN @AlGarfall @bdermanmd @OcioEnrique @NBahlis @MaiolinoAngelo @dra_v_hungria @nishjo76 11/Do results w isa show similar trends?
IMROZ🔑trial
IsaVRd➡️IsaRd v VRd➡️Rd in TIE pts w NDMM

👉IsaVRd ➡️↓time to MRD-: 14.7 v 32.8m
↑ PFS @ 60m: 63.2 v 45.2%; HR: 0.60; P<0.001
↑ CR: 74.7% v 64.1%; P=0.01

🎉IMROZ results support IsaVRd as 🆕SOC for TIE #NDMM pts
@szusmani

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT @AnnemiekBroijl @H_Einsele @PerrotAurore @paurotero @MyelomaOslo @mvmateos @AjayNookaMD @Bethfaiman @18m @mbeksac56 @hhashmi87 @docbraunstein @nsc_natalie @FaithEDavies1 @IreneGhobrial @SLentzsch @EliasKarlMai @andrew02114 @SurbhiSidanaMD @UrviShahMD @DrRakeshPopat @Dr_AmerZeidan @HarethNahi @EHA_Hematology @EMN_EuMMnet @NCCN @AlGarfall @bdermanmd @OcioEnrique @NBahlis @MaiolinoAngelo @dra_v_hungria @nishjo76 @szusmani @Myeloma_Doc @thanosdimop 12/BENEFIT eval'd wkly bortezomib (V) in TIE NDMM

IsaVRd➡️IsaVR➡️IsaR v IsaRd➡️IsaR➡️IsaR
↑MRD- rate @
12mo 51% v 21%; OR: 3.88; 95%CI: 2.27-6.62;P<0.0001
18mo 53% v 26%; OR: 3.16; 95%CI: 1.89-5.28;P<0.0001

🔑Wkly V in IsaRd=deep responses
Supports IsaVRd as🆕SOC for TIE NDMM

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT @AnnemiekBroijl @H_Einsele @PerrotAurore @paurotero @MyelomaOslo @mvmateos @AjayNookaMD @Bethfaiman @18m @mbeksac56 @hhashmi87 @docbraunstein @nsc_natalie @FaithEDavies1 @IreneGhobrial @SLentzsch @EliasKarlMai @andrew02114 @SurbhiSidanaMD @UrviShahMD @DrRakeshPopat @Dr_AmerZeidan @HarethNahi @EHA_Hematology @EMN_EuMMnet @NCCN @AlGarfall @bdermanmd @OcioEnrique @NBahlis @MaiolinoAngelo @dra_v_hungria @nishjo76 @szusmani @Myeloma_Doc @thanosdimop 13/🆕SOC for pts w SCT-deferred or TIE #NDMM🎉

NCCN (preferred, cat 1) & EHA-EMN (1st optn) regimens:
🎯DRd ‘til progression; de-escalate prn
🎯DVRd ‘til progression; de-escalate prn (<80 yr old, not frail)
🎯IsaVRd ‘til progression; de-escalate prn (<80 yr old, not frail)
#MMSM

[Krina Patel @DrKrinaPatel]

@BonumCe @BloodCancerCME @Global_CME @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT @AnnemiekBroijl @H_Einsele @PerrotAurore @paurotero @MyelomaOslo @mvmateos @AjayNookaMD @Bethfaiman @18m @mbeksac56 @hhashmi87 @docbraunstein @nsc_natalie @FaithEDavies1 @IreneGhobrial @SLentzsch @EliasKarlMai @andrew02114 @SurbhiSidanaMD @UrviShahMD @DrRakeshPopat @Dr_AmerZeidan @HarethNahi @EHA_Hematology @EMN_EuMMnet @NCCN @AlGarfall @bdermanmd @OcioEnrique @NBahlis @MaiolinoAngelo @dra_v_hungria @nishjo76 @szusmani @Myeloma_Doc @thanosdimop 14/Unfortunately, pts w high-risk (HR) #NDMM have 👎poorer prognosis & shorter survival rates vs standard-risk

Based on results of GMMG-CONCEPT presented at #ASCO2025, which treatment strategy should be used for pts w/ HR NDMM?

Key:
🔸MRD- = Treat to MRD-
#MMSM #OncTwitter